Basel, Switzerland, January 10, 2008 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced that in accordance with the further amendment of Section 505 of the Federal Food, Drug, and Cosmetic Act, ceftobiprole, as a new chemical entity (NCE), has been assigned a review by the FDA Anti-Infective Drug Advisory Committee on February 28th, 2008.
